B cell receptor signaling pathway and its therapeutic implications in B-cell lymphoma
10.3969/j.issn.1006-7795.2025.03.006
- VernacularTitle:B细胞受体信号通路在B细胞淋巴瘤中的作用及靶向治疗策略
- Author:
Jingwen WANG
1
;
Zhenjun LI
1
;
Liangcheng LYU
1
;
Xiaoyu YAO
1
;
Ning DING
1
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴瘤临床转化研究室,恶性肿瘤发病机制及转化研究教育部重点实验室,北京 100142
- Publication Type:Journal Article
- Keywords:
B-cell lymphoma;
B cell receptor;
signal pathway;
small molecule inhibitors;
immunotherapy
- From:
Journal of Capital Medical University
2025;46(3):436-441
- CountryChina
- Language:Chinese
-
Abstract:
B-cell lymphomas account for 70％-80％of non-Hodgkin lymphomas(NHL)and exhibit significant heterogeneity in genetic profiles,phenotypic characteristics,and clinical manifestations,posing substantial challenges for clinical management.The B-cell receptor(BCR)is a transmembrane receptor on the surface of B cells that plays a central regulatory role in B-cell development,activation,and adaptive immune responses.As a core mechanism driving malignant transformation in various B-cell malignancies,aberrant activation of the BCR signaling pathway,plays a pivotal role in B lymphoma pathogenesis.Dysregulated BCR signaling not only promotes tumor cell proliferation,survival,and anti-apoptotic capacity but also accelerates malignant progression.Consequently,researchers are vigorously exploring therapeutic strategies targeting BCR and its downstream pathways,including inhibitors of Bruton's tyrosine kinase(BTK)and PI3K,as well as direct BCR-targeted approaches.The central role of BCR signaling in lymphoma pathogenesis and treatment underscores its potential as a critical focus for future therapeutic development,offering new directions and hope for improved clinical outcomes.
